Enterprise Value

4.952B

Cash

600.5M

Avg Qtr Burn

-5.484M

Short % of Float

5.12%

Insider Ownership

1.75%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Vivitrol (naltrexone) Details
Alcohol dependence and opioid dependence treatment

Approved

Quarterly sales

LYBALVI (ALKS 3831) Details
Bipolar disease, Mental health, Schizophrenia

Approved

Quarterly sales

Nemvaleukin alfa (ALKS-4230) (IL-2) + KEYTRUDA (PD-1) Details
Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer

Phase 3

Update

Phase 2

Update

Failed

Discontinued